



**4<sup>th</sup> Annual TeCH HCC Symposium Agenda**  
**August 17<sup>th</sup>, 2024**

**9:00 AM – 3:00 PM CT**

**Baylor College of Medicine, McNair Campus, Houston, TX**



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**Theme:** HCC: From Prevention to Treatment

**Date:** August 17, 2024

**Format:** In-person with a virtual option (Hybrid)

**Location:** Baylor College of Medicine at McNair Campus, 7200 Cambridge St, Houston TX 77030

**Time:** 9:00 AM – 3:00 PM

**Target audience:** Clinical researchers, trainees, clinical providers, public health workers

**Sponsorship:** Genentech

**Baylor College of Medicine, McNair Campus, Houston, TX**

**Session I: Contemporary HCC Epidemiology and Impact on Prevention – Fasiha Kanwal, MD, MSHS (moderator)**

<b>Time</b>	<b>Topics</b>	<b>Speaker</b>	<b>Academic Title/Institution</b>	<b>Mode</b>
8:50 – 9:00	TeCH and HCC in Texas	Hashem B. El-Serag, MD, MPH	Chair and Professor, Department of Medicine, Baylor College of Medicine	In-person
9:00 – 9:12	Disparities in HCC	Nicole Rich, MD	Assistant Professor of Internal Medicine, UT Southwestern Medical Center	In-person
9:12 – 9:24	Genetic Predisposition to HCC	Aaron P. Thrift, PhD	Associate Professor, Department of Medicine, Baylor College of Medicine	In-person
9:24 – 9:36	Environmental exposures and HCC	Caitlin C. Murphy, PhD, MPH	Associate Professor, Department of Health Promotion & Behavioral Sciences, UTHealth School of Public Health Houston	In-person
9:36 – 9:48	Risk stratification: Identifying at risk individuals	Fasiha Kanwal, MD, MSHS	Professor and Section Chief, Department of Medicine, Baylor College of Medicine	In-person
9:48 – 10:00	Gut microbiome and the risk of HCC	Bernd Schnabl, MD	Professor, Department of Medicine, University of California San Diego	Virtual
10:00 – 10:20	Panel Discussion			
10:20 – 10:35	Coffee Break			

**Session II: HCC Prevention and Policy – Sumeet Asrani, MD, MSc (moderator)**

10:35 – 10:47	HCV Elimination programs and policy implementation in Texas	Parvez S. Mantry, MD	Medical Director, The Liver Institute at Methodist Dallas	In-person
10:47 – 10:59	Weight loss and obesity impact on HCC risk	Maya Balakrishnan, MD	Assistant Professor, Department of Medicine, Baylor College of Medicine	In-person
10:59 – 11:09	Alcohol impact on HCC risk	George Cholankeril, MD	Assistant Professor, Department of Medicine, Baylor College of Medicine	In-person
11:09 – 11:23	Chemoprevention of HCC: Metformin, ASA, GLP-1 agonists	Sumeet K. Asrani, MD, MSc	Medical Director, Center for Advanced Liver Disease	In-person



**4<sup>th</sup> Annual TeCH HCC Symposium Agenda**  
**August 17<sup>th</sup>, 2024**  
**9:00 AM – 3:00 PM CT**



CANCER PREVENTION & RESEARCH  
 INSTITUTE OF TEXAS

**Baylor College of Medicine, McNair Campus, Houston, TX**

			Baylor University Medical Center, Baylor Scott & White Health	
11:23 – 11:45	Panel Discussion			
11:45 – 12:30	<b>Lunch/Keynote: Lessons Learned from NCI: DCP, HEDS and TRACER Studies</b>	Sudhir Srivastava, PhD, MPH	Chief Program Officer, Division of Cancer Prevention, National Cancer Institute	Virtual

**Section III: HCC Screening – Amit Singal, MD (moderator)**

12:30 – 12:42	Underuse and interventions of HCC screening	Amit G. Singal, MD	Medical Director, Liver Tumor Program and Clinical Chief of Hepatology, UT Southwestern Medical Center	In-person
12:42 – 12:56	Abbreviated MRI for HCC screening	Takeshi Yokoo, MD, PhD	Medical Director, Magnetic Resonance Imaging Division and Associate Professor of Radiology, UT Southwestern Medical Center	In-person
12:56 – 1:08	Blood-based HCC biomarkers	Neehar Parikh, MD, MS	Associate Professor, Department of Gastroenterology & Hepatology, University of Michigan	Virtual
1:08 – 1:30	Panel Discussion			
1:30 – 1:40	Break			

**Section IV: HCC Treatment – Nicole Rich, MD (moderator)**

1:40 – 1:52	Expanding role of liver transplant for HCC and CCA	Maen Abdelrahim, MD, PhD	Gastrointestinal Medical Oncologist and Assistant Professor of Medicine in Oncology, Houston Methodist	In-person
1:52 – 2:04	Role of systemic earlier lines of HCC treatment (TACE/TARE therapies)	Mark Yarchoan, MD	Associate Professor of Oncology, Johns Hopkins Hospital	Virtual



**4<sup>th</sup> Annual TeCH HCC Symposium Agenda**  
**August 17<sup>th</sup>, 2024**  
**9:00 AM – 3:00 PM CT**

**Baylor College of Medicine, McNair Campus, Houston, TX**



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

2:04 – 2:16	Emerging (early clinical trial) treatments for HCC	Sukeshi Arora, MD	Associate Professor, Division of Hematology and Medical Oncology, The University of Texas Health Science Center San Antonio	In-person
2:16 – 2:28	Putting it together: Multi-disciplinary care programs for patients with HCC	Anjana Pillai, MD	Associate Professor, Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, The University of Chicago	Virtual
2:28 – 2:45	Panel discussion/Wrap Up Session			